Topcon Corporation
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Topcon Corporation sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,751 sponsors by registered trial count).
Topcon Corporation: 8 sponsored US clinical trials, none currently recruiting.
Topcon Corporation sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. The most-studied condition in this pipeline is Retina Condition Followed by Fluorescein Angiography Imaging, with 1 trials.
Upper-quartile sponsor footprint
Topcon Corporation sits in the upper quartile of the sponsor corpus (#1,604 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Agreement and Precision Study
NCT06733428
TRK-3 Performance of Pachymetry
NCT06250868
TRK-3 Conformance to Standards for Tonometers
NCT06247072
Screening Protocol
NCT06135727
NW500 Non-Mydriatic Retinal Camera Clinical Performance Study
NCT05286502
OCT Angiography Software Evaluation Study
NCT04701931
Topcon DRI OCT Triton With SS-OCT Angio Software Evaluation Study
NCT04201340
Triton Reference Database
NCT03067675
Therapeutic Areas
How the Topcon Corporation archive is shaped
8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Retina Condition Followed by Fluorescein Angiography Imaging (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.